You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ovarian Suppression

Showing 1 - 25 of 5,572
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian

Not yet recruiting
  • Hormone-receptor-positive Breast Cancer
  • +3 more
  • Aromatase inhibitor
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023

Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

Not yet recruiting
  • Breast Cancer
  • Ovarian Function Suppression + Aromatase Inhibitor
  • Adjuvant Chemotherapy + Ovarian Function Suppression
  • (no location specified)
May 19, 2023

Breast Cancer Survivors, Sexual Function Disturbances, Ovarian Suppression Treatment Trial in Boston (Group Session, Telephone

Completed
  • Breast Cancer Survivors
  • +2 more
  • Group Session
  • Telephone Booster
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Nov 11, 2021

Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer Trial in Seoul (Ovarian function suppression with

Not yet recruiting
  • Breast Cancer
  • +4 more
  • Ovarian function suppression with endocrine treatments
  • Seoul, Korea, Korea, Republic of
    Gangnam Severance Hospital
Dec 18, 2022

Breast Cancer Trial in Lexington, East Syracuse (TOL2506, Tamoxifen, Letrozole tablets)

Enrolling by invitation
  • Breast Cancer
  • Lexington, Kentucky
  • +1 more
Jan 9, 2023

Improve Sexual Health, Improve Vulvovaginal Health Trial in United States (questionnaires, moisturizers)

Recruiting
  • Improve Sexual Health
  • Improve Vulvovaginal Health
  • questionnaires
  • moisturizers
  • Basking Ridge, New Jersey
  • +6 more
Jun 9, 2023

Breast Cancer Invasive Trial in Seoul (Leuplin or zoladex)

Recruiting
  • Breast Cancer Invasive
  • Leuplin or zoladex
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 16, 2022

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Infertility, IVF, Preimplantation Diagnosis Trial in Barcelona (GnRh antagonist, Micronized progesterone)

Recruiting
  • Infertility
  • +2 more
  • GnRh antagonist
  • Micronized progesterone
  • Barcelona, Catalunya, Spain
    Institut Universitari Dexeus
Mar 29, 2022

Cognitive Impairment, Estrogen Deficiency, Menopause Trial in Aurora, Boulder (GnRHant + E2, GnRHant + Placebo)

Completed
  • Cognitive Impairment
  • +4 more
  • GnRHant + E2
  • GnRHant + Placebo
  • Aurora, Colorado
  • +1 more
Jun 3, 2021

Breast Cancer Trial in Shanghai (OFS + Anastrozole, OFS + Exemestane)

Completed
  • Breast Cancer
  • OFS + Anastrozole
  • OFS + Exemestane
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022

Metastatic Breast Cancer Trial in Seoul (Everolimus(afinitor), Letrozole, Leuprolide(Lorelin Depot))

Completed
  • Metastatic Breast Cancer
  • Seoul, Korea, Republic of
    Asan Medical Center
Jul 29, 2020

Single Follicular Dexarelix for LH Suppression During Ovarian

Recruiting
  • Infertility
  • Premature Ovarian Failure
  • live birth rate
  • Thessaloniki, Greece
    Assisting Nature
Oct 6, 2020

Metastatic Breast Cancer Trial in Johannesburg (Palbociclib, Exemestane, Goserelin)

Recruiting
  • Metastatic Breast Cancer
  • Johannesburg, South Africa
    Wits Oncology center
Jul 22, 2021

RWE About QOL and Compliance of Patients With OFS in China

Not yet recruiting
  • Breast Cancer
  • +2 more
  • 3M GnRHa
  • 1M GnRHa
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 15, 2021

Breast Cancer Trial in Shanghai (Neoadjuvant endocrine therapy, Neoadjuvant chemo)

Terminated
  • Breast Cancer
  • Neoadjuvant endocrine therapy
  • Neoadjuvant chemotherapy
  • Shanghai, Shanghai, China
    Ruijin Hospital
Mar 9, 2020

PCOS Trial in Zagazig (Injection of Cetrorelix, Oral insertion of dydrogeserone)

Completed
  • PCOS
  • Injection of Cetrorelix
  • Oral insertion of dydrogeserone
  • Zagazig, Ash Sharqia Governorate, Egypt
    Zagazig university
Jul 3, 2023

Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma Trial in Canada,

Active, not recruiting
Has Results
  • Estrogen Receptor Positive Breast Cancer
  • +7 more
  • Birmingham, Alabama
  • +499 more
Nov 15, 2022

Breast Cancer Trial in Guangzhou (Tucidinostat, Exemestane, Ovarian function suppression)

Unknown status
  • Breast Cancer
  • Guangzhou, Guangdong, China
    The first affiliated hospital of Sun Yat-Sen university
Jul 22, 2020

IVF, PCO Trial in Bani Suwayf (Dydrogesterone Tablets, Cetrorelix)

Not yet recruiting
  • IVF
  • PCO
  • Banī Suwayf, Beni Suef, Egypt
    Beni-suef university Hospital
Jul 16, 2023

Ovarian Suppression Trial in New York (Low dose formulation, High dose formulation)

Completed
Has Results
  • Ovarian Suppression
  • Low dose formulation
  • High dose formulation
  • New York, New York
    Columbia University Medical Center
Apr 16, 2019

Infertility Trial in Istanbul (Gonadotropin releasing hormone antagonist (Cetrotide), Medroxyprogesterone Acetate (Tarlusal),

Not yet recruiting
  • Infertility
  • Gonadotropin releasing hormone antagonist (Cetrotide)
  • +2 more
  • Istanbul, Turkey
    Bezmialem Vakif University
Mar 13, 2023

Poor Responders Trial in Bani Suwayf (myo-inositol, Somatropin, Dehydroepiandrosterone)

Not yet recruiting
  • Poor Responders
  • Banī Suwayf, Beni Suef, Egypt
    Beni-suef university Hospital
Jun 4, 2023

Fertility Trial in Barcelona (150µg CFA (Elonva®) at stimulation day (SD) 1 and 100µg CFA(Elonva®) at SD 5, 150µg CFA (Elonva®)

Not yet recruiting
  • Fertility
  • 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5
  • 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
  • Barcelona, Spain
    Hospital Universitario Quiron Dexeus
Nov 10, 2023

Female Breast Cancer Trial in Germany

Recruiting
  • Female Breast Cancer
    • Moenchengladbach, NRW, Germany
    • +4 more
    Mar 30, 2023